Allergy Therapeutics (LON:AGY) will later this month present data on its patented technology used in novel vaccines at the World Vaccine Congress in Madrid.
The conference takes place between November 9 and 11, and the company describes it as “an outstanding opportunity” for scientific debate and dialogue among industry specialists.
The data comes from active collaborations led by Professor Martin Bachmann at the University of Oxford and The Jenner Institute and also Dr Bassam Hallis at Public Health England.
It supports the use of the technology, depot adjuvant MCT, in novel vaccine candidate formulations including malaria and influenza, the company highlighted.
Allergy Therapeutics added that the findings include data relating to the strong absorption capacity, immunological relevance and stability profile of MCT, as well as compatibility with antigens and in adjuvant system complexes.
"We have been extremely fortunate to work with leading vaccine development experts through our collaborative projects with University of Oxford, The Jenner Institute and Public Health England,” said Dr Murray Skinner, Allergy Therapeutics chief scientific officer.
“This data further supports the potential that MCT, our patented formulation technology, has in a wide variety of therapeutic applications, offering unique biodegradable and immunological properties distinct from traditional delivery adjuvants many of which fail during product development owing to factors such as manufacturability, stability, lack of effectiveness and unacceptable levels of tolerability.”
Manuel Llobet, Allergy Therapeutics' chief executive, added: “A key component of our future strategy for growth has been to develop innovative adjuvanted vaccines and create new sales channels within our existing business.
“This data validates the use of our proprietary MCT technology in a potentially wide range of applications and is an important additional milestone in displaying our R&D capability, our differentiated approach and, ultimately, allowing us to grow our European market share over the coming years."